公开(公告)号：US20230039679A1

公开(公告)日：2023-02-09

申请号：US17939147

申请日：2022-09-07

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY

Inventor： Sung Youn CHANG ,  Hyuk LEE ,  Ki Young KIM ,  Bum Tae KIM ,  Sung Soo KIM ,  Seong Hwan KIM ,  Hwan Jung LIM ,  Jung Nyoung HEO ,  Sang Joon SHIN ,  Sang Youn PARK

IPC: C07D231/38 ,  A61P35/04 ,  C07D401/04 ,  C07D401/14 ,  C07D403/10 ,  C07D409/04 ,  C07D417/04

Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.

公开(公告)号：US20130123297A1

公开(公告)日：2013-05-16

申请号：US13734348

申请日：2013-01-04

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Nak Jeong KIM ,  Myung-Ae BAE ,  Sung-Eun YOO ,  Namsook KANG ,  Jung Nyoung HEO ,  Kyu Yang YI ,  Jee Hee SUH ,  Sung Youn CHANG ,  Eun Sook HWANG ,  Jeong-Ho HONG

IPC: C07D471/04 ,  C07D403/10

CPC classification number: C07D471/04 ,  A61K31/437 ,  C07D403/10

Abstract: A pharmaceutical composition comprising a phenyltetrazole derivative of formula (I) or a pharmaceutical acceptable salt thereof is effective in preventing or treating osteoporosis, obesity, diabetes, or hyperlipidemia, by regulating protein TAZ. wherein, A is ethyl or n-butyl; R1 is methyl, —CH2OH, —CO2CH3, —CH2F, —CH(OCH3)2, —CH2OC(═O)CH3, styryl or —CH2OCH2SCH3; R2 is H, Br, —CO2CH3, phenyl, pyridin-2-yl, pyridin-3-yl, or styryl; R3 is H or methyl; X is CH or N; and P is H or —CH(CH3)OCH2CH3.

Abstract translation: 通过调节蛋白质TAZ，包含式（I）的苯基四唑衍生物或其药学上可接受的盐的药物组合物可有效预防或治疗骨质疏松症，肥胖症，糖尿病或高脂血症。 其中A为乙基或正丁基; R1是甲基，-CH2OH，-CO2CH3，-CH2F，-CH（OCH3）2，-CH2OC（= O）CH3，苯乙烯基或-CH2OCH2SCH3; R 2是H，Br，-CO 2 CH 3，苯基，吡啶-2-基，吡啶-3-基或苯乙烯基; R3是H或甲基; X是CH或N; 并且P是H或-CH（CH 3）OCH 2 CH 3。

公开(公告)号：US20210047300A1

公开(公告)日：2021-02-18

申请号：US16967825

申请日：2019-01-31

Applicant: Korea Research Institute of Chemical Technology ,  Industry-Academic Cooperation Foundation, Yonsei University

Inventor： Sung Youn CHANG ,  Hyuk LEE ,  Ki Young KIM ,  Bum Tae KIM ,  Sung Soo KIM ,  Seong Hwan KIM ,  Hwan Jung LIM ,  Jung Nyoung HEO ,  Sang Joon SHIN ,  Sang Youn PARK

IPC: C07D403/12 ,  C07D413/14 ,  C07D401/12 ,  C07D403/14 ,  C07D413/12 ,  C07D417/14

Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.

公开(公告)号：US20210047277A1

公开(公告)日：2021-02-18

申请号：US16967844

申请日：2019-01-31

Applicant: Korea Research Institute of Chemical Technology ,  Industry-Academic Cooperation Foundation, Yonsei University

Inventor： Sung Youn CHANG ,  Hyuk LEE ,  Ki Young KIM ,  Bum Tae KIM ,  Sung Soo KIM ,  Seong Hwan KIM ,  Hwan Jung LIM ,  Jung Nyoung HEO ,  Sang Joon SHIN ,  Sang Youn PARK

IPC: C07D231/38 ,  C07D403/10 ,  C07D401/04 ,  C07D409/04 ,  C07D417/04 ,  C07D401/14 ,  A61P35/04

Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.